3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
60
Observational
1
Expanded_access
1
Sponsor
Cancer Type
Gastrointestinal
2
Thoracic
1
Gynecologic
1
Genitourinary
1
Conditions
Urologic Neoplasms
1
Urogenital Neoplasms
1
Recurrence
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma
1
Interventions
Surveys and Questionnaires
52
Blood Specimen Collection
47
enzalutamide
29
radium Ra 223 dichloride
22
Biopsy
20
darolutamide
19
Radiotherapy
19
Docetaxel
19
apalutamide
18
Sunitinib
18
Magnetic Resonance Spectroscopy
18
Sorafenib
17
Abiraterone Acetate
17
Watchful Waiting
16
Interviews as Topic
15
Gene Expression Profiling
15
Amplified Fragment Length Polymorphism Analysis
15
Observation
13
Leuprolide
13
Immunohistochemistry
13
Androgen Antagonists
13
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
12
Magnetic Resonance Imaging
12
avelumab
11
Specimen Handling
11
abiraterone
9
Polymerase Chain Reaction
9
Flow Cytometry
9
Radiosurgery
8
Microarray Analysis
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Mitomycin
×
Genitourinary
×
Clear all
NCT05874921
2025-02-28
uTRACT
UroGen Pharma Ltd.
Recruiting
400 enrolled